Skip to main content

Pablo Castillo Sánchez

Institutions of which they are part

Research technician
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Pablo Castillo Sánchez

Institutions of which they are part

Research technician
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Projects

NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson's and Gaucher's disease

IP: Marta Martínez Vicente
Collaborators: Mercedes Arrúe Gonzalo, Maria Camprodon Gomez, Pablo Castillo Sánchez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 42000
Reference: 2024 PROD 00073
Duration: 02/12/2024 - 01/06/2026

NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson´s and Gaucher's disease

IP: Marta Martínez Vicente
Collaborators: Mercedes Arrúe Gonzalo, Jorge Hernández Vara, Maria Camprodon Gomez, Jordi Riera Heredia, Pablo Castillo Sánchez
Funding agency: Fundació "La Caixa"
Funding: 24440
Reference: CI24-20222
Duration: 01/10/2024 - 30/09/2026

New nanotechnological therapy for Parkinson ?s disease: nose to brain delivery of GBA-polymer nanoconjugates

IP: Marta Martínez Vicente
Collaborators: Pablo Castillo Sánchez, Laia Perez Lasarte
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 73383.97
Reference: AGAUR/FI/2023/CASTILLO
Duration: 01/06/2023 - 31/05/2026

New nanotechnological therapy for Parkinson's disease: nose-to-brain delivery of GBA-polymer nanoconjugates (NANOGBAtoBRAIN)

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Eddie Pradas Gracia, Laura Castillo Ribelles, Clara Carnicer Cáceres, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Pablo Castillo Sánchez
Funding agency: Fundació "La Caixa"
Funding: 249950
Reference: HR22-00602
Duration: 01/11/2022 - 31/10/2025

Related news

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Related professionals

Marta Caballe Montilla

Marta Caballe Montilla

Research assistant
Psychiatry, Mental Health and Addictions
Read more
Mar Baz Montero

Mar Baz Montero

Predoctoral researcher
Psychiatry, Mental Health and Addictions
Read more
Jon Esandi Jauregui

Jon Esandi Jauregui

Predoctoral researcher
Gene Therapy at Nervous System
Read more
Diego Gonzalez Morado

Diego Gonzalez Morado

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.